New Ivermectin meta analysis. Very thorough, so read all before nitpicking:
-Meta analysis using the most serious outcome reported shows 67% [53‑76%] and 86% [75‑92%] improvement for early
treatment and prophylaxis, with similar results after exclusion based sensitivity analysis (which excludes all of the GMK/BBC team studies), with primary outcomes, and after restriction to peer-reviewed studies or Randomized Controlled Trials.
-There is evidence of a negative publication bias, and the probability that an ineffective treatment generated results as positive as the 64 studies is estimated to be 1 in 222 billion.
- Over 20 countries have adopted ivermectin for COVID-19. The evidence base is much larger and has much lower conflict of
interest than typically used to approve drugs.
-Additional upcoming trials including ACTIV-6, COVID-OUT, and PRINCIPLE have been designed in a way that favors finding no effect, with a number of methods including late treatment, selecting low-risk patients, fasting administration, very high conflict of
interest medication sourcing, and dosing below current clinical practice
Conclusion:
Ivermectin is an effective treatment for COVID-19. Treatment is more effective when used early. Meta analysis using the most serious outcome reported shows 67% [53‑76%] and 86% [75‑92%] improvement for early treatment and prophylaxis, with similar results after exclusion based sensitivity analysis (which excludes all of the GMK/BBC team studies), with primary outcomes, and after restriction to peer-reviewed studies or Randomized Controlled Trials. Statistically significant improvements are seen for mortality, ventilation, ICU admission, hospitalization, recovery, cases, and viral clearance. All remain statistically significant after exclusions. 31 studies show statistically significant improvements in isolation. Results are very robust — in
worst case exclusion sensitivity analysis 53 of 64 studies must be excluded to avoid finding statistically significant efficacy.